MedTrace Logo

Neural Gliders With and Without ESWT for Deep Gluteal Syndrome

NCT07772674 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2026-08-21

No results posted yet for this study

Summary

This study is a randomized controlled trial comparing Neural Gliders with and without Extracorporeal Shock Wave Therapy (ESWT) in patients with Deep Gluteal Syndrome. A total of 44 participants are divided equally into two groups: Group A receives neural gliders, ESWT, and conventional physiotherapy, while Group B receives neural gliders with conventional physiotherapy only. The study evaluates changes in pain, functional disability, and nerve mechano-sensitivity using NPRS, ODI, LEFS, Slump Test, FAIR Test, and SLR. Its aim is to determine whether adding ESWT provides greater clinical improvement than neural gliders alone.

Conditions

  • Deep Gluteal Syndrome

Interventions

OTHER

Group A= Neural Gliders with ESWT

We use Neural Gliders in Deep Gluteal Syndrome because the sciatic nerve can become irritated or restricted as it passes through the deep gluteal region. Neural gliding produces gentle alternating movements that allow the nerve to slide within its pathway, helping improve nerve mobility, reduce mechano-sensitivity, improve circulation around the nerve, and decrease pain and functional limitation. We combine Neural Gliders with ESWT because the two interventions target different components of the problem. Neural gliders mainly address nerve mobility and sensitivity, while ESWT is intended to act on the surrounding deep gluteal/piriformis tissues by helping reduce pain, improve blood flow, decrease tissue tightness, and stimulate healing.

OTHER

Group B= Neural Gliders without ESWT

We use neural gliders to improve sciatic nerve mobility and reduce nerve mechano-sensitivity. We add ESWT because it may reduce pain, improve circulation, and treat tight or restricted deep gluteal tissues. Therefore, the combination may address both the nerve and the surrounding soft tissues more effectively."

Sponsors & Collaborators

  • University of Management and Technology Sialkot Pakistan

    lead OTHER

Principal Investigators

  • Hamza Zahid, MS OMPT · University of Management and Technology Sialkot Pakistan

  • Danyal Ahmad, PhD Scholar · University of Management and Technology Sialkot Pakistan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
25 Months
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-15
Primary Completion
2026-08-25
Completion
2026-09-30

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07772674 on ClinicalTrials.gov